FY2026 EPS Forecast for Immunovant Increased by Analyst

Immunovant, Inc. (NASDAQ:IMVT) – Equities researchers at HC Wainwright upped their FY2026 EPS estimates for Immunovant in a report issued on Tuesday, February 10th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($2.66) for the year, up from their prior estimate of ($3.04). HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Immunovant’s current full-year earnings is ($2.69) per share. HC Wainwright also issued estimates for Immunovant’s Q4 2026 earnings at ($0.61) EPS, Q1 2027 earnings at ($0.69) EPS, Q2 2027 earnings at ($0.70) EPS, Q3 2027 earnings at ($0.62) EPS, Q4 2027 earnings at ($0.66) EPS, FY2027 earnings at ($2.68) EPS, FY2028 earnings at ($2.69) EPS and FY2029 earnings at $0.03 EPS.

Immunovant (NASDAQ:IMVT) last issued its quarterly earnings results on Friday, February 6th. The company reported ($0.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.11. During the same period in the previous year, the business posted ($0.76) EPS.

A number of other equities analysts have also commented on the stock. Wolfe Research upgraded shares of Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a report on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a research report on Friday, January 9th. Guggenheim increased their target price on Immunovant from $41.00 to $44.00 and gave the company a “buy” rating in a research note on Monday. The Goldman Sachs Group lifted their price target on shares of Immunovant from $18.00 to $28.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. Finally, Truist Financial increased their price objective on shares of Immunovant from $16.00 to $22.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.11.

Immunovant Price Performance

NASDAQ IMVT opened at $25.64 on Friday. Immunovant has a 1-year low of $12.72 and a 1-year high of $27.92. The firm has a market capitalization of $5.22 billion, a P/E ratio of -9.53 and a beta of 0.54. The business’s 50-day simple moving average is $25.92 and its 200-day simple moving average is $20.99.

Insider Transactions at Immunovant

In other news, insider Tuyl Christopher Van sold 10,813 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $26.91, for a total transaction of $290,977.83. Following the transaction, the insider directly owned 149,930 shares in the company, valued at $4,034,616.30. The trade was a 6.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CTO Jay S. Stout sold 1,977 shares of the company’s stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $26.03, for a total value of $51,461.31. Following the completion of the transaction, the chief technology officer directly owned 197,634 shares in the company, valued at approximately $5,144,413.02. The trade was a 0.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 63,868 shares of company stock worth $1,538,470. 1.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Immunovant by 8.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,971 shares of the company’s stock worth $708,000 after purchasing an additional 3,348 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Immunovant by 48.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,007,700 shares of the company’s stock valued at $17,222,000 after buying an additional 329,354 shares in the last quarter. Strs Ohio acquired a new stake in shares of Immunovant in the first quarter worth about $27,000. Aberdeen Group plc increased its holdings in shares of Immunovant by 3.1% during the 2nd quarter. Aberdeen Group plc now owns 844,705 shares of the company’s stock valued at $13,515,000 after acquiring an additional 25,228 shares during the last quarter. Finally, TD Asset Management Inc raised its stake in shares of Immunovant by 5.5% in the 2nd quarter. TD Asset Management Inc now owns 192,506 shares of the company’s stock valued at $3,080,000 after acquiring an additional 10,108 shares in the last quarter. Institutional investors own 47.08% of the company’s stock.

Immunovant News Summary

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: HC Wainwright raised multiple quarterly and annual EPS forecasts for Immunovant, trimming expected losses across 2026–2028 and projecting a small positive EPS of $0.03 in FY2029 (up from -$0.36). The firm also increased FY2030 to $2.91 and kept a “Buy” rating with a $35 price target — a clear analyst vote of confidence that the company’s path to profitability may be sooner than previously modeled. Article Title
• Neutral Sentiment: HC Wainwright specifically tightened quarterly EPS estimates (examples: Q1–Q4 2026/2027 and Q3 2027 revised from about -$0.90 to -$0.62 in some quarters), reflecting improved modeled revenue/cost assumptions — this is constructive but remains forecast-based (not yet realized results). Article Title
• Neutral Sentiment: Short‑interest reports show an anomalous increase with values reported as 0 shares/NaN changes — appears to be a data/reporting glitch rather than a meaningful short‑selling signal; investors should treat these filings cautiously until clarified by exchanges or filings.
• Neutral Sentiment: Context: Immunovant recently beat the prior quarter’s EPS consensus (reported -$0.61 vs. -$0.72 est.), and consensus full‑year estimates still reflect losses (~-$2.69). Analyst upgrades improve the tone, but the company remains in a loss‑making phase where clinical/regulatory and commercialization execution will ultimately drive the stock.

About Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.